Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 7:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 20,701 matching trials from the live ClinicalTrials.gov search.
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Adriamycin, vinblastine, and dacarbazine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography, Docetaxel, PSMA PET Scan, Single Photon Tomography and Computed Tomography Scan, Biospecimen Collection
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Results available

Preventing Acute Chest Syndrome by Transfusion Feasibility Study

NCT00951808
Conditions
Sickle Cell Disease
Interventions
Single blood transfusion, Standard care
Biological · Behavioral
Lead sponsor
Carelon Research
Other
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 14 more
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
21,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Terminated Phase 1Phase 2 Interventional Results available

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

NCT00089076
Conditions
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
ipilimumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Melanoma (Skin)
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
156
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 98 more
Terminated Not applicable Interventional Accepts healthy volunteers

Glycemic Index of Commonly Consumed Sweeteners

NCT02931578
Conditions
Healthy
Interventions
Glucose100, Glucose50, Glucose42, Oral Glucose Tolerance Test
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Open Posterior Thoracolumbar Spinal Fusion Procedure
Interventions
Tranexamic Acid Injectable Product (1000 mg intravenous bolus), Vitamin C 250 MG Oral Tablet, Tranexamic Acid 650Mg Tablet
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Leukemia
Interventions
filgrastim, cladribine, idarubicin
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
Interventions
Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 2 Interventional Accepts healthy volunteers

Pistachios Blood Sugar Control, Heart and Gut Health

NCT04056208
Conditions
Type 2 Diabetes, Cardiovascular Diseases
Interventions
Pistachio, Usual care
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Conditions
Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Siltuximab
Procedure · Biological
Lead sponsor
Timothy Voorhees
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Chronic Pain, Hypertension, Implanted Stimulation Electrodes
Interventions
Diagnostic Tests
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
30 Years to 89 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Fairway, Kansas • Kansas City, Kansas
Conditions
Neurodevelopmental Abnormality
Interventions
Umbilical Cord Milking, Early Cord Clamping
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
22 Months to 26 Months
Enrollment
1,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Davis, California • Loma Linda, California • San Diego, California + 3 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation

NCT00075335
Conditions
Healthy
Interventions
AMD3100 (Mozobil plerixafor)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Achilles Injuries Tendon
Interventions
Standard of Care Physical Therapy, Blood flow restriction
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Not listed Not applicable Interventional Accepts healthy volunteers

Immunological Effect of Increasing Doses of Natural Peptide

NCT05176678
Conditions
Pharmacokinetics
Interventions
1 gram of a protein hydrolysate, 2 grams of a protein hydrolysate, 4 grams of a protein hydrolysate, 8 grams of a protein hydrolysate
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
25 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Klamath Falls, Oregon
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Donor, Lymphoblastic Lymphoma, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Thiotepa, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Seattle, Washington
Conditions
Renal Cell Carcinoma
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Bakersfield, California • Fullerton, California + 35 more
Conditions
Leukemia, Not Otherwise Specified, Leukemia, Other
Interventions
Cyclophosphamide, Specimen collection
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2035
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Carcinoma, Small Cell Lung
Interventions
irinotecan, carboplatin, bevacizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Fort Myers, Florida • Cincinnati, Ohio • Chattanooga, Tennessee + 1 more
Conditions
Aids-related Malignancies, Lymphoma, Precancerous Condition, Sarcoma
Interventions
polymerase chain reaction, cytology specimen collection procedure, histological technique, colposcopic biopsy
Genetic · Other · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 5 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
Device · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Mesa, Arizona • Bakersfield, California • Huntington Beach, California + 36 more
Completed Not applicable Interventional Results available

Role of Neutrophil Activation

NCT01815229
Conditions
Patients Requiring Endotracheal Intubation
Interventions
tracheal lavages
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri